PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Pfizer, MedImmune, Roche, and Bristol-Myers Squibb intended to find methods to enable prediction and prevention of PML associated with immunomodulatory and immunosuppressive treatments.
2015 Conference Proceedings Published Proceedings of the August 2015 research conference and recordings of presentations are now available here.
Review Article Published “Progressive Multifocal Leukoencephalopathy: Current Treatment Options and Future Perspectives,” authored by members of the PML Consortium Clinical and Research Working Groups, has been published in Therapeutic Advances in Neurological Disorders. Access the full article via PubMed.